HOME2020-06-08T11:37:23+01:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Team PD-MitoQUANT raises funds and runs for Parkinson’s Association of Ireland

October 19th, 2020|

A team of Irish women involved in the PD-MitoQUANT project completed the Vhi Virtual Women’s Mini-Marathon to benefit the Parkinson’s Association of Ireland (https://www.parkinsons.ie/). Partners at the RCSI, Royal College of Surgeons in Ireland and Pintail Limited coordinated their efforts on October 2, 2020.  To date, €770 was raised by [...]

PD-MitoQUANT researchers take part in Parkinsons’-UK online conference

October 6th, 2020|

The theme of the 2-day 2020 Parkinson's-UK conference was "Accelerating research and improving care." Keynote lectures were delivered live from around the world. Several researchers from PD-MitoQUANT partner organisations were involved. At the September 24th and 25th meeting, research was presented by Prof Donato Di Monte of the German [...]

Read more
Go to Top